In fact, however, the IRB exists thanks to two important private donations. On the one hand, the Horten foundation of the homonymous German philanthropist with 10 million francs: it is chaired by Alberto Togni, a member of the management of UBS from Ticino. The agreement with the foundation provides that 40% of the proceeds of the activity are given to the canton.
Max Burger, scientific director of the pharmaceutical giant Novartis, also sits on the scientific board of the Horten foundation. Burger also sat on the scientific council of the institute but with "separate functions" from Novartis, specifies the IRB. There is also the Italian nobel Renato Dulbecco, researcher and lecturer at the Salk Institute in San Diego, who already collaborates with Novartis.
Burger's deputy is Hans Ulrich Dörig, vice president of the board of Credit Suisse, member of the board of directors of the University of Zurich and close to the economic lobbies
In 2002 Usi and Irb entered into partnerships with the Italian research center in Siena of the American vaccine giant Chiron, another Novartis partner. This has been collaborating for years with the Basel Institute of Immunology, owned by the Roche group and formerly directed by Lanzavecchia, who also teaches at the University of Siena; and the Californian Stanford University, where one of the authors of the "human mouse" studied.
Given the billions at stake, the business could only attract the attention of banks and shareholders. The Bank of Italian Switzerland (Bsi) has invested 620,000 francs in the IRB for 4 years: in exchange it receives advice on its investment fund in shares "new biomedical frontier" and its director, Gianni Aprile, sits in the Board of Trustees of Irb. The current director of Banca Stato, Donato Barbuscia, is instead a member of the Biopolo Ticino.
Market Data 
Markets 
AI
